Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 196
Population
196 Ugandan children aged 3-6 years
Methods
randomized, double-blind, placebo-controlled trial, consuming 125 ml daily of either probiotic yogurt containing Lacticaseibacillus rhamnosus yoba 2012 and Streptococcus thermophilus C106 or a non-fermented dairy placebo over nine weeks
Blinding
Double-blind
Duration
9 weeks
Funding
Unclear
  • Large Human Trial
  • Rigorous Journal
This study evaluated the effects of locally produced probiotic yogurt on infectious diseases in Ugandan children aged 3-6 years. Over nine weeks, 196 children participated in a randomized, double-blind, placebo-controlled trial, consuming 125 ml daily of either probiotic yogurt containing Lacticaseibacillus rhamnosus yoba 2012 and Streptococcus thermophilus C106 or a non-fermented dairy placebo. The primary outcome, average daily incidence of upper respiratory tract symptoms, showed no significant difference between groups. However, the probiotic yogurt group experienced a significant reduction in respiratory tract infection symptoms over time (p = 0.02). Biomarker analysis revealed significant changes in the probiotic yogurt group, including higher urine hippurate levels (p = 0.02), increased lactic acid bacteria (p = 0.04) and total bacterial load (p = 0.04) in stool, and elevated SLPI (p = 0.005) in saliva from baseline to endline. Despite these within-group effects, the lack of significant differences between the yogurt and placebo groups highlights the need for further research with larger cohorts and longer durations to confirm the potential benefits of this probiotic yogurt for reducing infection symptoms and improving health biomarkers under these study conditions.

Research Insights

    Back to top